COMMUNIQUÉS West-GlobeNewswire

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase
15/01/2026
Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in Shenzhen LAS VEGAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. ( OTCID: CBSC ) (“CBSC” [...]
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
15/01/2026
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for advanced cancer [...]
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
15/01/2026
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report ® for 2025-26 [...]
Verano Announces Agreement to Upsize Revolving Credit Facility Commitment to $100,000,000 and Extend Maturity Date
15/01/2026
Amendment adds incremental $25,000,000 and extends maturity date from September 29, 2028 to February 28, 2029 CHICAGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or [...]
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
15/01/2026
This milestone marks significant progress in the first-in-human evaluation of AAVantgarde’s dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1B LONDON and MILAN, Jan. 15 [...]
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
15/01/2026
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first [...]
Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
15/01/2026
Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical Partner BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology [...]
Zelluna ASA: Approval and publication of prospectus
15/01/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs
15/01/2026
Actuarial claims analysis confirms up to 9X ROI across GLP-1, Metabolic, and GI Costs, demonstrating the power of gut microbiome and genetics-based biomarker care MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE [...]
Verdane Invests in Clue to Accelerate the Future of Women’s Health
15/01/2026
BERLIN, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Clue, the #1 women-led period and cycle tracker health and wellness app, with over 100 million downloads worldwide, today announced a significant and strategic investment from [...]
Press Release: Myqorzo and Redemplo approved in China
15/01/2026
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-term commitment to China, reinforcing [...]
Communiqué de presse : Myqorzo et Redemplo approuvés en Chine
15/01/2026
Myqorzo et Redemplo approuvés en Chine Approbation de Myqorzo pour la cardiomyopathie hypertrophique obstructive et de Redemplo pour le syndrome de chylomicronémie familiale. Souligne l’engagement à long terme de Sanofi [...]
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
15/01/2026
Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved [...]
Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market
15/01/2026
LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of [...]
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
15/01/2026
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, [...]
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
15/01/2026
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of [...]
New site in Lommel, Belgium: Aqua free successfully completes set-up phase with ISO 9001 certification
14/01/2026
Lommel / Hamburg, 01/15/2026 – Aqua free , a leading provider of innovative drinking-water hygiene solutions, has successfully moved into its new, state-of-the-art facility in Lommel and has now also obtained ISO 9001 [...]
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
14/01/2026
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global [...]
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
14/01/2026
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients. 1 ,2 [...]

Pages